Start with the source
Health Canada’s April 2026 public advisory warns consumers about unauthorized injectable peptide drugs sold online and promoted for anti-aging, weight loss, bodybuilding, recovery, sleep, focus, and wellness.
The advisory gives examples of products seized by Health Canada, including BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-C, TB-500, and retatrutide. Being named in an advisory is a regulatory signal about unauthorized products—it is not a clinical comparison of every peptide’s research record.
What “research use only” does not mean
Health Canada explicitly says it continues to identify products labelled “For Research Use Only – Not for Human Consumption,” and that this wording does not make them legal or exempt from regulatory requirements.
That is why this publication does not publish vendor lists, purchasing links, discount codes, reconstitution guidance, or self-administration instructions. A disclaimer cannot turn promotional material into neutral education.
How we will report this beat
Regulatory status and evidence are separate questions. A product’s authorization status does not prove a particular outcome, and an interesting mechanism does not establish that an unauthorized product is safe or effective.
Every Canada-status note on this site should name a primary source and a checked date. When an authorized drug is relevant, readers should be able to verify it in Health Canada’s Drug Product Database.
Primary sources
- Health Canada advisory ↗Primary public advisory; updated Apr. 9, 2026.
- Drug Product Database ↗Health Canada database for products authorized for sale.
- Special Access Program overview ↗Program context; not a route for self-directed use.